ArticlePloS one2015
Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review.Journal of viral hepatitis · 2018Pooled it
- Trial
- Impact ofFrontiers in cellular and infection microbiology · 2026Article
- Hepatitis C virus-associated B-cell non-Hodgkin lymphomas: immune evasion, multistep lymphomagenesis, and candidate biomarkers for risk stratification and disease monitoring.Frontiers in immunology · 2026Review
- Genome tuning through HLA and KIR gene clusters impact susceptibility to dengue.Infectious medicine · 2023Review
- Non-Classical HLA Class 1b and Hepatocellular Carcinoma.Biomedicines · 2023Review
- Risk Assessment and Cholangiocarcinoma: Diagnostic Management and Artificial Intelligence.Biology · 2023Review
- Imaging Features of Main Hepatic Resections: The Radiologist Challenging.Journal of personalized medicine · 2023Review
- Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence.Cancers · 2023Review
- Percutanous Electrochemotherapy (ECT) in Primary and Secondary Liver Malignancies: A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
- Influence of killer immunoglobulin-like receptors genes on the recurrence rate of ocular toxoplasmosis in Brazil.Memorias do Instituto Oswaldo Cruz · 2023Article
- A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls.Diagnostics (Basel, Switzerland) · 2022Review
- Decoding the diversity of killer immunoglobulin-like receptors by deep sequencing and a high-resolution imputation method.Cell genomics · 2022Article
- KIR2DL2, KIR2DL5A and KIR2DL5B Genes Induce Susceptibility to Dengue Virus Infection, while KIR3DL3 and KIR2DS5 Confer Protection.Mediterranean journal of hematology and infectious diseases · 2022Article
- Maternal natural killer cells at the intersection between reproduction and mucosal immunity.Mucosal immunology · 2021Review
- Investigation of the Effect of KIR-HLA Pairs on Hepatocellular Carcinoma in Hepatitis C Virus Cirrhotic Patients.Cancers · 2021Article
- Influence of HLA-C environment on the spontaneous clearance of hepatitis C in European HIV-HCV co-infected individuals.Clinical and experimental immunology · 2021Article
- Gender as a factor affecting NK cell activity in patients successfully treated for chronic hepatitis C with direct-acting antivirals.Central-European journal of immunology · 2021Article
- An immunogenetic view of COVID-19.Genetics and molecular biology · 2021Article
- Genetic Variants inFrontiers in immunology · 2021Article
Corrections and comments
- Erratum issuedCorrection: Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases.2015 · Beretta, Massimiliano [corrected to Berretta, Massimiliano]
Authors and funding
22 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe variability in the association of host innate immune response to Hepatitis C virus (HCV) infection requires ruling out the possible role of host KIR and HLA genotypes in HCV-related disorders: therefore, we therefore explored the relationships between KIR/HLA genotypes and chronic HCV infection (CHC) as they relate to the risk of HCV-related hepatocarcinoma (HCC) or lymphoproliferative disease progression. METHODS AND
findingsWe analyzed data from 396 HCV-positive patients with CHC (n = 125), HCC (118), and lymphoproliferative diseases (153), and 501 HCV-negative patients. All were HIV and HBV negative. KIR-SSO was used to determine the KIR typing. KIR2DL5 and KIR2DS4 variants were performed using PCR and GeneScan analysis. HLA/class-I genotyping was performed using PCR-sequence-based typing. The interaction between the KIR gene and ligand HLA molecules was investigated. Differences in frequencies were estimated using Fisher's exact test, and Cochran-Armitage trend test. The non-random association of KIR alleles was estimated using the linkage disequilibrium test. We found an association of KIR2DS2/KIR2DL2 genes, with the HCV-related lymphoproliferative disorders. Furthermore, individuals with a HLA-Bw6 KIR3DL1+ combination of genes showed higher risk of developing lymphoma than cryoglobulinemia. KIR2DS3 gene was found to be the principal gene associated with chronic HCV infection, while a reduction of HLA-Bw4 + KIR3DS1+ was associated with an increased risk of developing HCC.
conclusionsOur data highlight a role of the innate-system in developing HCV-related disorders and specifically KIR2DS3 and KIR2D genes demonstrated an ability to direct HCV disease progression, and mainly towards lymphoproliferative disorders. Moreover the determination of KIR3D/HLA combination of genes direct the HCV progression towards a lymphoma rather than an hepatic disease. In this contest IFN-α therapy, a standard therapy for HCV-infection and lymphoproliferative diseases, known to be able to transiently enhance the cytotoxicity of NK-cells support the role of NK cells to counterstain HCV-related and lymphoproliferative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.